Etelcalcetide

Etelcalcetide (AMG 416; KAI-4169) is a synthetic calcimimetic as an activator of the calcium sensing receptor (CaSR) . Etelcalcetide is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis, which is promising for research in the field of secondary hyperparathyroidism and chronic kidney disease[1][2].

Product Specifications

CAS Number

[1262780-97-1]

Product Name Alternative

Velcalcetide; AMG 416; KAI-4169

UNSPSC

12352209

Hazard Statement

H302-H312-H332

Target

CaSR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/etelcalcetide.html

Solubility

10 mM in DMSO

Smiles

N=C(N)NCCC[C@H](C(N)=O)NC([C@@H](C)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](CCCNC(N)=N)NC([C@@H](C)NC([C@H](NC(C)=O)CSSC[C@H](N)C(O)=O)=O)=O)=O)=O)=O)=O

Molecular Formula

C38H73N21O10S2

Molecular Weight

1048.25

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1][1]Van Megen WH, et al. Differential parathyroid and kidney Ca2+-sensing receptor activation in autosomal dominant hypocalcemia 1[J]. EBioMedicine. 2022 Apr;78:103947. |[2]Fujioka A, et al. Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells[J]. J Bone Miner Metab. 2021 May;39 (3) :396-403.